The median, minimum and maximum of the proportion of the Canadian population (%) that may require antiviral treatment during a pandemic after considering the circulation of non-influenza viruses that produce acute respiratory symptoms (including any of the following: runny nose, sneezing, sore throat, cough, cervical lymphadenopathy, fever, malaise, myalgia, loss of appetite, headache, and/or chills for scenarios where viral emergence occurs in the spring or in the fall/winter [61].

TX = treatment, m = months until vaccine availability in Canada.